



It takes Tau to Tangle

October 10, 2016

AC Immune's partner Genentech has published an editorial which summarizes the biology of Alzheimer's disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published [in Cell Reports by Gai Ayalon et al.](#)

[Please read and watch the videos "It takes Tau to Tangle" here.](#)

AC Immune and Genentech have been partners for a decade:

- In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.
- In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune's anti-Tau antibodies.

You can find out more about our collaborations [on our Partners page](#).